Apellis Pharmaceuticals Inc., a company focused on autoimmune and inflammatory diseases, has reported that APL-2, its complement C3 inhibitor in development for geographic atrophy (GA) linked to age-related macular degeneration (AMD), has met its primary endpoint in a Phase II trial (FILLY). The company now plans to use recently raised funds to initiate a Phase III trial in late 2018, in addition to progressing other pipeline products.
Apellis Eyes Progress For Lead AMD Product
Apellis Pharmaceuticals' lead product APL-2 for geographic atrophy, a progressed form of age-related macular degeneration, has met its primary endpoint in a Phase II trial with the company planning to begin Phase III trials in 2018.
More from Clinical Trials
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.
More from R&D
• By
Bharat Biotech is the latest entrant in India’s cell and gene therapy space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?
• By
Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.